Tycel Phillips
0000-0003-2143-9672
6 papers found
Refreshing results…
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB/II study
Burkitt Lymphoma International Prognostic Index
Missing publications? Search for publications with a matching author name.